Objective: To study the association between psoriasis and coronary artery disease, and to compare the rate of coronary artery disease in a group of Jordanian patients with moderate to severe psoriasis to that in a group of non-psoriatic patients.
Introduction
Psoriasis is a chronic inflammatory disease that affects 1-3% of the population worldwide. It is characterized by Th1/Th17-driven inflammation which stimulates tumor necrosis factor (TNF-α) and other mediators. This impairs proliferation and differentiation of keratinocytes, and cause abnormal skin vascularization. The most common clinical variant is psoriasis vulgaris, characterized by well demarcated erythematous plaques covered by silvery scales mainly on the scalp, face, elbows, knees, palms, and soles. Other variants include nail psoriasis, inverse psoriasis, pustular psoriasis, guttate psoriasis, and sero-negative psoriatic arthritis.
Regarding severity, psoriasis is classified into mild, moderate, and severe psoriasis. Psoriasis is considered moderate to severe if psoriasis area severity index (PASI) score was 10 or more, patients were hospitalized or received systemic medication for psoriasis.
(3)
Psoriasis is well-known to be associated with many co-morbidities including arthritis, Crohn's disease, cutaneous T-cell lymphoma, metabolic syndrome (atherogenic dyslipidemia, hypertension, abdominal obesity, diabetes and insulin resistance), predisposition to thrombosis, nonalcoholic hepatic steatosis, anxiety, depression, smoking, and alcoholism. Recently, psoriasis has also been thought of as a systemic inflammatory condition, with similarities to rheumatoid arthritis and systemic lupus erythematosus.
Since the risk of coronary artery disease (CAD) is increased in these diseases, it was logic to assume similar association between CAD and psoriasis.
Not only are CAD risk factors more prevalent in psoriasis, but even after these risk factors are controlled for, CAD is still more prevalent in psoriasis. Psoriasis group included 157 Jordanian patients with moderate to severe psoriasis, including psoriatic arthritis. Psoriasis was considered moderate to severe if PASI score was 10 or more; patients were hospitalized or received systemic medication for psoriasis. Control group included 183 Jordanian patients without psoriasis who were selected from the same centers.
After making adjustments for age, sex and risk factors of CAD (smoking, hypertension, diabetes, hyperlipidemia, and family history of CAD), rates of CAD in both groups were estimated and compared. Eleven out of the 156 psoriatic patients were found to have CAD, with estimated rate of 7.0%. On the other hand, the rate of CAD in nonpsoriasis group was found to be 1.6% (3/183). The difference was statistically significant with P-value<0.001.
These results are summarized in Table I .
Discussion
Psoriasis is a chronic inflammatory skin disorder with multisystem involvement.
In addition to the economic burden, psoriasis impairs the physical and psychological wellbeing of the patient, reducing his quality of life and work productivity.
(1,2) Psoriasis is well known to be associated with many comorbidities, one of which could be CAD. In our study, as shown in (Table I ), 7.0% of the patients in psoriasis group (11/156) were found to have CAD. On the other hand, CAD rate in non-psoriasis group was 1.6% (3/183). This difference is statistically significant (Pvalue<0.001).
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No. 2 June 2014 This finding is consistent with the study of Kimball et al, (5) among other studies, (6, 7, 8) that demonstrate that, like in other Th1-mediated inflammatory diseases, e.g. systemic lupus erythematosus and rheumatoid arthritis, CAD is more common in psoriatic patients, especially severe cases, than in the general population.
The cause of this association is unclear. Gisondi et al (6) and other authors (7, 8, 9) suggest that to be due to increased prevalence of CAD risk factors (obesity, smoking, hypertension, diabetes, hyperlipidemia, and family history of CAD) among psoriatic patients.
In our study, the patients in both groups were controlled for these risk factors. Regarding CAD risk factors, rates and P-values showed no statistically significant difference between psoriasis group and non-psoriasis group (see Table I ).
Our results are compatible with the work of Ahlehoff et al, (10) and other studies, (11,12,13) that showed psoriasis to be independently associated with CAD. These studies showed psoriasis and atherosclerosis to have the same etiology, which is increased Th1-mediated inflammation and dysangiogenesis.
This concept is further supported by the studies that demonstrated that systemic therapies for psoriasis decrease the risk of cardiovascular events, (14, 15, 16) and other studies which showed psoriatic patients to have increased carotid intima-media thickness and endothelial dysfunction, and increased levels of prothrombotic markers, which play a key role in atherosclerosis. 
Conclusion
Our study may add to the strength of evidence that CAD is associated with psoriasis, but this conclusion cannot be generalized for all psoriatic patients, because our study was based on data from patients with a moderate to severe psoriasis, but not mild psoriasis. Other studies are needed to determine the risk of CAD in patients with milder skin disease.
